deltatrials
Completed PHASE2 NCT00003116

High-Dose Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Allogeneic Peripheral Blood Progenitor Cell Transplantation Using Histocompatible Sibling-Matched Donor Cells After High-Dose Busulfan/Cyclophosphamide as Therapy for Hematologic Malignancies

Sponsor: Case Comprehensive Cancer Center

Conditions Leukemia Lymphoma Multiple Myeloma and Plasma Cell Neoplasm Myelodysplastic Syndromes Myelodysplastic/Myeloproliferative Diseases
Interventions bone marrow ablation with stem cell support busulfan cyclophosphamide cyclosporine filgrastim peripheral blood stem cell transplantation
Updated 6 times since 2017 Last updated: Jun 9, 2010 Started: May 31, 1997 Primary completion: Mar 31, 2006 Completion: Jun 30, 2009

Listed as NCT00003116, this PHASE2 trial focuses on Leukemia and Lymphoma and remains completed. Sponsored by Case Comprehensive Cancer Center, it has been updated 6 times since 1997, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE2

▶ Show 1 earlier version

  1. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

May 1997

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Case Comprehensive Cancer Center
  • National Cancer Institute (NCI)
Data source: Case Comprehensive Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Cleveland, United States